An underground market for unapproved slimming drugs is propelled by social media fitness personalities and vendors on communication apps, according to new investigations.
Experimental Drug Gaining Popularity Via Social Media
Retatrutide, which is still in clinical trials, is being promoted by online personalities for its supposed weight-reducing effects. Followers are encouraged to message these accounts directly for supplier links, while also receiving discount codes.
Thriving Commerce on Social Networks
Separately, a robust market exists on messaging services, where groups with thousands of members share comparison images, administration instructions and assertions of next-day UK delivery. Sellers promote the substance there before redirecting buyers to other platforms for transactions.
Learning About The Experimental Drug
Retatrutide is an investigational injectable created by US drugmaker Eli Lilly. The treatment affects three intestinal hormones – GLP-1, GIP and glucagon. Preliminary studies indicate it could help individuals reduce up to a quarter of their total weight. Referred to as the “triple G”, the drug is being hailed digitally as the next Ozempic.
Medical Experts Voice Concerns
However, physicians and chemists have cautions that the distribution of what remains an unapproved medication in the United Kingdom is a cause for concern and could result in users administering substances of unknown origin.
Some experts stated the popularity for retatrutide could be linked to the increasing cost of licensed slimming products such as Mounjaro.
Legal Status and Enforcement
Marketing the unapproved drug on social media or messaging apps is illegal in the United Kingdom, as it is an unlicensed medication that cannot be marketed or distributed for human use under the Human Medicines Regulations 2012.
Some influencers attempt to sidestep the regulations by referring to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted drug, but promotion and distribution can still breach medicines, marketing, and customer regulations, potentially leading to penalties, prosecution or imprisonment.
Platform Response and Content Removal
Based on the social media company, the service has removed problematic material and banned related hashtags and search suggestions. The company stated it was dedicated to maintaining the platform safe and allocating resources in strengthening compliance measures.
Digital Marketplace Activities
Investigations also found communities with up to nine thousand participants selling retatrutide using Telegram's built-in discovery tool, which operates like a public directory. Entering “retatrutide” instantly brings up channels with thousands of users, populated with photos of weight loss, positive reviews and step-by-step instructions for preparing or administering at home.
Within minutes of entering one group, a seller shared WhatsApp details, where the majority of purchases take place. The seller sent an instruction manual and promised shipping within two days. When questioned whether the product was authentic, one vendor responded: “You can’t be sure.” Another shared a image of a alleged laboratory certificate. None inquired about weight, medical conditions or past usage.
Product Details and Pricing
Inside these groups, posts display black plastic packages with Royal Mail stickers, stating to include new batches. One communication stated: “It took eight of us to load them this morning.”
Buyers can choose between dry substance containers, prepared at residence with purified liquid, or pre-filled injectors typically sold at 160 pounds for 20mg. When asked how long a pen should last, sellers give contradictory answers ranging from a few weeks to “depends on your body”.
Platform Oversight and Security Measures
A representative for the messaging service said it regularly monitored dangerous content on its platform including material that encouraged the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”.
Medical Professional Warnings
“People are injecting materials they cannot confirm. Even if the research behind retatrutide is valid, these digital products may not include what they claim,” said Jason Murphy, the director of pharmacy at a pharmacy service.
Dr Crystal Wyllie of an online medical service linked the increase in interest to recent cost increases for authorized weight-loss medications such as Mounjaro. “With prices increasing, patients are turning to online platforms. But counterfeit treatments are extremely risky. You cannot know what’s contained or whether the conditions they were produced in was sterile,” she said.
Her staff has already seen individuals injured by self-injection from unverified sources. “We understand the disappointment, but purchasing from messaging apps or WhatsApp is taking chances with your health,” said the doctor. “These substances could be contaminated or improperly measured.”
Manufacturer Position
A representative from the pharmaceutical company said the substance was in third stage clinical trials and had not been reviewed or authorized by any regulatory agency globally. “Therefore at this time no one can sell [it] for personal consumption,” they said, noting that any product “misleadingly claiming itself as a company investigational substance not yet authorized … may subject patients to possibly significant medical dangers”.
